A sign-and-close reverse merger leaves Bolt's original stockholders with 6.9% of the company as Prana's IL-4Rα/TSLP bispecific inherits the Nasdaq listing, backed by a $120 million placement closing today.
Top stories
Newsletter
Pipeline, markets, policy, and science. Once a week.
Wound care is becoming one of big medtech's next frontiers, and Swedish wound-care leader Mölnlycke just announced a separation into an independent wound-care company. At the center of that landscape sits MediWound (NASDAQ: MDWD).
Lilly's Jaypirca just won frontline CLL with a large survival edge, but only over chemoimmunotherapy the field is retiring. Lilly itself says the drug belongs in second line, and that sequencing logic shapes what the new label is really worth.
FDA expanded Anktiva's use to BCG-unresponsive, high-grade papillary-only bladder cancer without a dedicated trial, leaning on earlier carcinoma in situ data and scientific similarities. The move sets a precedent developers of rare indications will study closely.
In depth
A Nature paper finds that one arginine transfer RNA, tRNA1 Arg(UCU), keeps prostate tumors on androgen receptor signaling. When it falls, cells slip into a lineage-plastic, AR-inhibitor-resistant state.
Read the storyMirum's brelovitug hit its Phase 3 endpoint in hepatitis delta, but Gilead's Hepcludex already holds the US approval and Vir's program is in flight. A strong readout no longer guarantees the market follows.
Celcuity's REVTORPYK became commercially available September 30, claiming the PIK3CA wild-type corner of second-line HR-positive breast cancer no approved PI3K or AKT label covers. The launch must now overcome an immature survival read, heavy stomatitis, and a weekly IV schedule.
The FDA granted accelerated approval to AstraZeneca’s camizestrant based on ctDNA resistance signals before radiographic progression, overruling a 6-3 advisory committee vote and betting on a new oncology paradigm.
Conjugating antisense oligonucleotides to transferrin receptor transport vehicles achieves fifty-fold deeper brain penetration, challenging the standard of invasive spinal punctures.
